EP0855445B1 - Dihydroxycholesterine und verfahren zur herstellung von hydrolierten cholesterinen durch biologische umwandlung - Google Patents

Dihydroxycholesterine und verfahren zur herstellung von hydrolierten cholesterinen durch biologische umwandlung Download PDF

Info

Publication number
EP0855445B1
EP0855445B1 EP96927894A EP96927894A EP0855445B1 EP 0855445 B1 EP0855445 B1 EP 0855445B1 EP 96927894 A EP96927894 A EP 96927894A EP 96927894 A EP96927894 A EP 96927894A EP 0855445 B1 EP0855445 B1 EP 0855445B1
Authority
EP
European Patent Office
Prior art keywords
cholesterol
formula
cyclodextrin
added
dihydroxycholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96927894A
Other languages
English (en)
French (fr)
Other versions
EP0855445A4 (de
EP0855445A1 (de
Inventor
Koji Takeda
Tadashi Terasawa
Kazuyuki Dobashi
Takeo Yoshioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mercian Corp
Original Assignee
Mercian Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp filed Critical Mercian Corp
Publication of EP0855445A1 publication Critical patent/EP0855445A1/de
Publication of EP0855445A4 publication Critical patent/EP0855445A4/de
Application granted granted Critical
Publication of EP0855445B1 publication Critical patent/EP0855445B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/06—Hydroxylating

Definitions

  • the present invention relates to a method for hydroxylating cholesterol by the action of microorganisms, and more specifically to a method for preparing one or more of either 25-hydroxycholesterol, 17,25-dihydroxycholesterol or 25,26-dihydroxycholesterol from cholesterol.
  • the invention also relates to the aforementioned new dihydroxycholesterols.
  • a biological method for preparing hydroxy-derivatives of steroids including cholesterol by means of microorganisms, a method by which cholesterol is converted into 25-hydroxycholesterol using microorganisms of the genus Streptomyces has been disclosed in Japanese Laid-Open Patent Publication No. 123997/95.
  • the biological conversion which is interesting, of compounds other than steroids, there are known the methods for preparing 25-hydroxyvitamin D compounds by the hydroxylation of vitamin D compounds using microorganisms, for example, Nocardia autotrophica , Streptomyces roseosporus , Amycolata saturnea , Amycolata autotrophica , Sphingomonas sp. (Japanese Laid-Open Patent Publication Nos. 166090/92, 241197/95).
  • cholesterol may be, for example, an intermediate on the chemical synthesis of various kinds of vitamin D compounds (Yuki Gosei Kagaku (Organic Synthetwic Chemistry) 37 , 809-829 (1979)), and compounds wherein one or more of the specific sites of cholesterol is/are hydroxylated beforehand may be expected for their use as intermediates on the synthesis of various hydroxylated vitamin D compounds.
  • Yuki Gosei Kagaku Organic Synthetwic Chemistry
  • none of the cited prior art documents teaches the method of the present invention.
  • hydroxylation efficiency is not always satisfactory. From the view point of improving the water-solubility of final compounds derived from cholesterol, for example, vitamin D compounds, it would be also desired to provide not only mono-hydroxylated cholesterols but also further hydroxylated cholesterols, for example, dihydroxylated cholesterols.
  • the purpose of the present invention is therefore to provide a method for efficiently preparing mono-hydroxylated cholesterols, in particular 25-hydroxycholesterol, and a method for preparing further hydroxylated dihydroxycholesterols, and new dihydroxycholesterols per se.
  • the above purpose can be achieved by providing a method, by which cholesterol having formula (I) is biologically converted into hydroxylated cholesterols of formula (II) (in which R 1 is a hydroxyl radical, and R 2 and R 3 are a hydroxyl radical and a hydrogen atom, respectively, or a hydrogen atom and a hydroxyl radical, respectively), for preparing hydroxylated cholesterols having the formula (II), according to the invention, comprising
  • dihydroxycholesterols of formula (II-b) (in which R 2 and R 3 are a hydroxyl radical and a hydrogen atom, respectively, can be also prepared by another method in which 25-hydroxycholesterol is substituted for cholesterol as a starting material in the above method.
  • dihydroxycholesterol having the above formula (II-b) that is, 17, 25-dihydroxycholesterol, is a compound that has not been published in literature in the prior art. Therefore, according to the present invention, a new compound, dihydroxycholesterol having the formula (II-b), is also provided.
  • microorganisms and their preparations from cultures can be used, regardless of the kinds of species and strains, provided that they are microorganisms belonging to the genus Amycolata and the genus Sphingomonas and having the capacity to convert cholesterol of the above formula (I) into hydroxylated cholesterols of the formula (II).
  • paucimobilis IFO 13935, parapaucimobilis IFO 15100, yanoikuyae IFO 15102, adhaesiva IFO 15099, sanguis IFO 13937, macrogoltabidus IFO 15033 and terrae IFO 15098 can be used to obtain 25-hydroxycholesterol (formula (II-a)).
  • IFO is a deposition number in the Institute for Fermentation in Japan.
  • cholesterol (the compound of formula (I)) and/or 25-hydroxycholesterol (the compound of formula (II-a)) being a starting material (or a substrate) will be treated by incubation in the presence of any of said strains or their mycelia from cultures and oxygen.
  • This treatment can be carried out by adding a substrate, at the time of the cultivation of the above strain under the aerobic conditions; into a culture solution, or optionally by adding a substrate into a suspension of, for example, the mycelia as such or the homogenized preparations obtained from cultures of the above strains, followed by incubation with oxygen, for example, with air.
  • the addition of a substrate into a culture solution may be performed either before the cultivation or at a certain period of time after the cultivation.
  • the above mycelia can be prepared by inoculating any of the above strains into a medium containing nutrient sources, followed by aerobic cultivation.
  • the cultivation of a strain to obtain such bacterial preparation from cultures or the cultivation of a strain carried out with the addition of a substrate can be performed, in principle, in accordance with cultivation methods for general microorganisms, but it is usually preferable to be carried out under aerobic conditions such as shaking liquid culture, aerated and stirred culture, etc.
  • the media used for the cultivation may be those containing nutrient sources which can be utilized by microorganisms belonging to the genus Amycolata and the genus Sphingomonas , and any of various kinds of synthetic or semi-synthetic media or natural media can be used.
  • nutrient sources which can be utilized by microorganisms belonging to the genus Amycolata and the genus Sphingomonas
  • any of various kinds of synthetic or semi-synthetic media or natural media can be used.
  • glucose, maltose, xylose, fructose and sucrose can be used alone or in combination as carbon sources.
  • organic nitrogen sources such as peptone, meat extract, soybean meal, casein, amino acids, yeast extract and urea
  • inorganic nitrogen sources such as sodium nitrate and ammonium sulfate can be used alone or in combination.
  • salts such as sodium chloride, potassium chloride, calcium carbonate, magnesium sulfate, sodium phosphate, potassium phosphate and cobalt chloride , salts of heavy metals, vitamins can also be used.
  • various known defoamers can be also added suitably into a medium.
  • Cultivation conditions can be suitably selected so that said strains can grow well.
  • the cultivation are performed at pH 6-7.5, at 28-30°C for approximately 2-8 days.
  • Various cultivation conditions described above can be suitably changed depending on the kind and property of a microorganism used and external conditions and optimized conditions can be easily selected by those skilled in the art.
  • bacterial preparation from cultures is prepared by suspending mycelia, which has been separated by centrifugation or filtration, or homogenized mycelia in an appropriate solution.
  • Solutions that can be used for suspending mycelia are the media as described above or buffer solutions such as tris-acetate, tris-hydrochloride, sodium succinate, sodium citrate, sodium phosphate and potassium phosphate and they are used alone or in admixture.
  • buffer solutions such as tris-acetate, tris-hydrochloride, sodium succinate, sodium citrate, sodium phosphate and potassium phosphate and they are used alone or in admixture.
  • pH values of the buffer solution preferably 6.0-9.0 and more preferably 7.0-8.5 can be mentioned.
  • a substrate can be added into a culture solution or a bacterial suspension in the form of powder or by dissolving in water-soluble organic solvent, for example and ethanol, and the amount to be added, for example, in the case of a culture solution, is preferably 0.15-0.60 mg per 1 ml of the culture solution. When the amount is increased to more than 0.60 mg/ml, conversion rate becomes slow and is not preferable.
  • the substrate can be converted into an objective hydroxylated cholesterol by carrying out the operation of shaking or aeration-agitation at 27-31°C for 1-3 days, preferably approximately for one day, to allow the reaction to proceed under aerobic conditions. In such a conversion reaction, the conversion rate into an objective hydroxylated cholesterol from a substrate can be remarkably increased by adding the substrate and methylated cyclodextrins to a reaction solution.
  • the incubation treatment described above is therefore carried out further in the presence of methylated cyclodextrins.
  • Methylated cyclodextrins used according to the invention refer to compounds wherein hydrogen atoms of hydroxyl radicals at the 2-, 3- or 6-position of cyclodextrin are substituted by methyl radicals, and hexakis-(2,6-0-dimethyl)- ⁇ -cyclodextrin derived from ⁇ -cyclodextrin, heptakis-(2, 6-0-dimethyl) - ⁇ -cyclodextrin derived from ⁇ -cyclodextrin and octakis-(2,6-0-dimethyl)- ⁇ -cyclodextrin derived from ⁇ -cyclodextrin, which are completely methylated at the 2- and 6-positions, or hexakis-(2,3,6-0-trimethyl)- ⁇ -cyclodextrin derived from ⁇ -cyclodextrin, heptakis-(2,3,6-0-trimethyl)- ⁇ -cyclodextrin derived from ⁇ -cyclodext
  • any methylated cyclodextrins is/are selected from those described above and used, but, in particular, partially methylated cyclodextrin derived from ⁇ -cyclodextrin is preferably used.
  • the amount of methylated cyclodextins added is 0.5 mg or more, preferably 0.5-15 mg, and more preferably 1-10 mg per 1 ml of a reaction solution.
  • the amount of the methylated cyclodextrins added is less than 0.5 mg per 1 ml of a reaction solution, there are sometimes cases where the increase in conversion rate into an objective hydroxylated cholesterol does not become significant compared to that without the addition, and for the amount in the region of 15 mg, foaming takes place in some cases, and it may become necessary to use a defoamer etc. together.
  • nonionic surfactants may be added into a reaction mixture so as not to decrease the conversion rate described above.
  • a surfactant of polyoxyethylene ⁇ sorbitan fatty acid ester (e.g., Tween R 80 (Sigma)), sorbitan fatty acid ester (e.g., Span R 85 (Sigma)), polyoxyethylene ether (e.g., Brij R 96 (Sigma)) and Triton R X-100 (Sigma), nonylphenol (e.g., Nonypol R 45 (Sanyo Chemical Industries Ltd.), block copolymer of ethylene oxide-propylene oxide (e.g., Pluronic R L-61 (Asahi Denka Kogyo K.K.), and Dislex R (Nippon Oil and Fats Co. Ltd.) and as an anionic sufactant, Trax R (Nippon Oil and Fats Co. Ltd.).
  • polyoxyethylene ⁇ sorbitan fatty acid ester e.g., Tween R
  • an objective hydroxylated cholesterol thus produced from a reaction mixture
  • various known purification procedures can be selected and carried out in combination. For example, it can be separated and purified by means of adsorption to hydrophobic adsorption resins and elusion, extraction with solvent using ethyl acetate, n-butanol etc., a column chromatography with silica gel etc. or thin layer chromatography, preparative high performance liquid chromatography using a reversed phase column and these can be used alone or suitably in combination, or optionally used repeatedly.
  • Amycolata saturnea FERM BP-5544 which is one of the strains being able to be used particularly advantageously in the abovementioned biological conversion, was isolated from soil by the present inventors, and named A-1246 strain, and it is a new strain as described below showing bacteriological properties as follows:
  • Vegetative mycelium develops well on synthetic or natural agar media and branches irregularly. No septum is observed. Spore chains are formed abundantly on glycerin-asparagine agar media and starch-inorganic salts agar media. By microscopic observation, sporulating mycelium branches monopodially with straight spore chains. Usually, the spore chains have three or more spores, and the long spore chains are developed at the late growth phase of the culture with smooth surfaces. The spore is cylindrical in shape and 0.5-0.8 x 2.5-4.3 ⁇ m in size. Sclerotia, sporangia and flagellated spore are not observed.
  • the cell wall of this strain belongs to the type III according to the classification by Lechevalier (International Journal of Systematic Bacteriology, vol. 20, p435-443 (1970)). Mycolic acid is not contained.
  • this strain belongs to Actinomycetes , and when these properties were compared with those of known microorganisms reported in the International Journal of Systematic Bacteriology, Vol.36, p29-37 (1986), this strain was almost identical to Amycolata saturnea. As a result of the above, this strain is concluded to belong to Amycolata saturnea , and named an Amycolata saturnea A-1246 strain.
  • a seed culture medium consisting of 1.5% of glucose, 1.5% of Bacto®-soyton (Difco), 0.5% of corn steep liquor, 0.4% of sodium chloride and 0.2% of calcium carbonate (pH 7.0) was placed in a 500 ml Erlenmeyer flask and autoclaved at 120°C for 20 minutes.
  • This medium was inoculated with 2 ml of a frozen inoculum of an Amycolata saturnea A-1246 strain (FERM BP-5544) and shaking culture was carried out at 220 rpm for 48 hours at 28°C, thus a seed culture solution being prepared.
  • Example 2 Fifteen mg of cholesterol in the form of powder was added in Example 1.
  • Example 2 150 mg of cholesterol was suspended in 4 ml of ethanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Example 3 150 mg of cholesterol was suspended in a mixture of 1 ml of Tween 80 (surfactant: Sigma) and 3 ml of ethanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Tween 80 surfactant: Sigma
  • examples 4 there were added 15 mg of cholesterol, 1 ml of Tween 80 and 5.6 ml of a 1.5% aqueous solution of each cyclodextrin which was sterilized beforehand (121°C, 20 minutes).
  • Example 7 there were added 15 mg of cholesterol, 1 ml of Tween 80 and a 1.5 % aqueous solution of partially methylated ⁇ -cyclodextrin (methylation rate 74%: Mercian Corp.), which was sterilized beforehand (121°C, 20 minutes), at each determined concentration.
  • a seed culture medium consisting of 1.5% of glucose, 1.5% of Bacto®-soyton (Difco), 0.5% of corn steep liquor, 0.4% of sodium chloride and 0.2% of calcium carbonate (pH 7.0) was placed in a 500 ml Erlenmeyer flask and autoclaved at 120°C for 20 minutes.
  • This medium was inoculated with 2 ml of a frozen inoculum of an Amycolata saturnea A-1246 strain (FERM BP-5544) and shaking culture was carried out at 220 rpm for 48 hours at 28°C, thus a seed culture solution being prepared.
  • a conversion culture medium consisting of 2.0% of glucose, 0.2% of yeast extract, 0.5% of peptone, 1.0% of soybean meal, 0.5% of corn steep liquor, 0.04% of potassium secondary phosphate, 0.04% of sodium chloride, 0.2% of calcium carbonate and 0.05% of Silicon KM75 (defoamer: Shin-Etsu Chemical Co., Ltd.) (pH 7.4) was placed in each of five 3 1 mini-jar and sterilized by heating at 120°C for 20 minutes. Each medium was inoculated with 30 ml of the seed culture solution prepared above and cultivation was carried out for 48 hours at the temperature of 28°C, at the agitation of 400 rpm and at the aeration of 1.0 vvm.
  • the resulting powder was dissolved in the lower layer of chloroform-methanol-water (7:13:8) and purified by centrifuged liquid-liquid partition chromatography (CPC model NMF, 250W x 12: Sanki Engineering Co., Ltd.) using this two-layer system: Portions where a spot was observed at the Rf value of about 0.5 in the TLC analysis as in Example 1 were collected and concentrated to dryness, giving 168.2 mg of white powder.
  • the resulting powder was dissolved in methanol at a concentration of 0.1 mg/ml and subjected to a HPLC analysis under the following conditions, single peak with the retention time of about 17.9 minutes being observed. This retention time was in agreement with that of a standard product of 25-hydroxycholesterol (Sigma).
  • a seed culture solution was prepared as in Examples 1-9.
  • a conversion culture medium consisting of 2.0% of glucose, 0.2% of yeast extract, 0.5% of peptone, 1.0% of soybean meal, 0.5% of corn steep liquor, 0.04% of potassium secondary phosphate, 0.04% of sodium chloride, 0.2% of calcium carbonate and 0.05% of Silicon KM75 (defoamer: Shin-Etsu Chemical Co., Ltd.) (pH 7.4) was placed in a 3 1 mini-jar and sterilized by heating at 120°C for 20 minutes. This medium was inoculated with 30 ml of the seed culture solution prepared above and cultivation was carried out for 48 hours at the temperature of 28°C, at the agitation of 400 rpm and at the aeration of 1.0 vvm.
  • a seed culture medium consisting of 1.5% of glucose, 1.5% of Bacto®-soyton (Difco), 0.5% of corn steep liquor, 0.4% of sodium chloride and 0.2% of calcium carbonate (pH 7.0) was placed in a 500 ml Erlenmeyer flask and autoclaved at 120°C for 20 minutes.
  • This medium was inoculated with 2 ml of a frozen inoculum of an Amycolata saturnea A-1246 strain (FERM BP-5544) and shaking culture was carried out at 220 rpm for 48 hours at 28°C, thus seed culture solution being prepared.
  • Example 29 Fifteen mg of cholesterol in the form of powder was added in Example 29.
  • Example 30 150 mg of cholesterol was suspended in 4 ml of ethanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Example 31 150 mg of cholesterol was suspended in a mixture of 1 ml of Tween 80 (surfactant: Sigma) and 3 ml of ethanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Tween 80 surfactant: Sigma
  • 3 ml of ethanol dispersed by sonication
  • 0.4 ml of the suspension was added.
  • Examples 32, 33 and 34 there were added 15 mg of cholesterol, 1 ml of Tween 80 and 5.6 ml of a 1.5% aqueous solution of each cyclodextrin which was sterilized beforehand (121°C, 20 minutes).
  • Example 35, 36 and 37 there were added 15 mg of cholesterol, 1 ml of Tween 80 and a 1.5 % aqueous solution of partially methylated ⁇ -cyclodextrin (methylation rate 74%: Mercian Corp.), which was sterilized beforehand (121°C, 20 minutes), at each determined concentration.
  • a seed culture solution was prepared as in Examples 1-9.
  • a conversion culture medium consisting of 2.0% of glucose, 0.2% of yeast extract, 0.5% of peptone, 1.0% of soybean meal, 0.5% of corn steep liquor, 0.04% of potassium secondary phosphate, 0.04% of sodium chloride, 0.2% of calcium carbonate and 0.05% of Silicon KM75 (defoamer: Shin-Etsu Chemical Co., Ltd.) (pH 7.4) was placed in a 3 1 mini-jar and sterilized by heating at 120°C for 20 minutes. This medium was inoculated with 30 ml of the seed culture solution prepared above and cultivation was carried out for 48 hours at the temperature of 28°C, at the agitation of 400 rpm and at the aeration of 1.0 vvm.
  • a seed culture solution was prepared as in Examples 1-9.
  • Example 53 Fifteen mg of cholesterol in the powder form was added in Example 53.
  • Example 54 150 mg of cholesterol was suspended in 4 ml of ethanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Example 55 150 mg of cholesterol was suspended in a mixture of 1 ml of Tween 80 (surfactant: Sigma) and 3 ml of methanol, dispersed by sonication, and 0.4 ml of the suspension was added.
  • Tween 80 surfactant: Sigma
  • Example 56, 57 and 58 there were added 15 mg of cholesterol, 1 ml of Tween 80 and 5.6 ml of a 1.5% aqueous solution of each cyclodextrin which was sterilized beforehand (121°C, 20 minutes).
  • Examples 59, 60 and 61 there were added 15 mg of cholesterol, 1 ml of Tween 80 and a 1.5% aqueous solution of partially methylated ⁇ -cyclodextrin (methylation rate 74%: Mercian Corp.), which was sterilized beforehand (121°C, 20 minutes), at each determined concentration.
  • 25 26-dihydroxycholesterol in the culture solution was quantified by the same method as Examples 53-61.
  • the conversion rates into 25, 26-dihydroxycholesterol from cholesterol were summarized in Table 9.
  • the mixture of 2,6-di-0-methyl- ⁇ -cyclodextrin and 2,4,6-tri-0-methyl-p-cyclodextrin were used at the ratios of 2:1 and 1:2, respectively.
  • Conversion rate (%) Example No. Coexisting substance Methylation rate (%) 16hr 40hr 64hr 62 -- -- 0.0 0.
  • a seed culture solution and a conversion culture medium were prepared similarly to those in Examples 1-9, except that a strain used was replaced with each strain which is shown in Table 11, and partially methylated ⁇ -cyclodextrin was added so as to be a final concentration of 1.0 %.
  • the concentration of cholesterol added was made to be 300 ⁇ g/ml and the culture was carried out at the pH and the reaction time which are shown in Table 11 below.
  • the measurements of the substrate cholesterol and the hydroxylated cholesterols obtained were carried out in accordance with those in the above Examples. The results were summarized in Table 11.
  • hydroxylated cholesterols including 25-hydroxycholesterol can be efficiently prepared, and 17, 25-dihydroxycholesterol is provided as a new hydroxylated cholesterol.
  • These compounds are useful, for example, as intermediates for the preparation of vitamin D compounds and would be applicable in manufacturing industries for medicaments.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (8)

  1. Verfahren zur Herstellung hydroxylierter Cholesterine der Formel (II):
    Figure 00400001
    (worin R1 eine Hydroxylgruppe bedeutet und R2 und R3 eine Hydroxylgruppe bzw. ein Wasserstoffatom oder ein Wasserstoffatom bzw. eine Hydroxylgruppe bedeuten) durch biologische Umwandlung von Cholesterin der Formel (I):
    Figure 00400002
    umfassend
    (A) eine Stufe, in der die zuvor erwähnte biologische Umwandlung durchgeführt werden kann und bei der Cholesterin der Formel (I) durch Inkubation in Anwesenheit eines Stammes, ausgewählt aus Mikroorganismen, die zu der Gattung Amycolata und der Gattung Sphingomonas gehören, oder ihrer Präparation aus Kulturen und Sauerstoff behandelt wird, wobei der Stamm der Gattung Sphingomonas die Fähigkeit besitzt, Cholesterin in hydroxylierte Cholesterine der Formel (II) zu überführen, und
    (B) eine Stufe, bei der mindestens eines der Hydroxylcholesterine der Formel (II) aus der durch Inkubation behandelten Lösung gewonnen wird.
  2. Verfahren nach Anspruch 1, wobei die zuvor erwähnten Mikroorganismen, die zu der Gattung Amycolata gehören, Mikroorganismen sind, die zu Amycolata saturnea oder Amycolata autotrophica gehören.
  3. Verfahren nach Anspruch 1, wobei die zuvor erwähnten Mikroorganismen, die zu der Gattung Sphingomonas gehören, ausgewählt werden aus der Gruppe bestehend aus Sphingomonas mali und Sphingomonas capsulata.
  4. Verfahren nach Anspruch 1, wobei die Inkubationsbehandlung bei der Stufe (A) die Behandlung von Cholesterin der Formel (I) in den Kulturen der zuvor erwähnten Mikroorganismen ist.
  5. Verfahren nach Anspruch 1, wobei die Inkubationsbehandlung bei der Stufe (A) in Anwesenheit methylierter Cyclodextrine durchgeführt wird.
  6. Verfahren zur Herstellung eines Dihydroxycholesterins der Formel (II-b):
    Figure 00410001
    (worin R2 und R3 eine Hydroxylgruppe bzw. ein Wasserstoffatom bedeuten)
    durch biologische Umwandlung von 25-Hydroxycholesterin der Formel (II-a):
    Figure 00420001
    (worin R2 ein Wasserstoffatom bedeutet),
    umfassend
    (A) eine Stufe, in der die zuvor erwähnte biologische Umwandlung durchgeführt werden kann und bei der 25-Hydroxycholesterin der Formel (II-a) durch Inkubation in Anwesenheit eines Stamms, ausgewählt aus Mikroorganismen, die zu der Gattung Amycolata und der Gattung Sphingomonas gehören, oder ihrer Präparation aus Kulturen und Sauerstoff behandelt wird, und
    (B) eine Stufe, bei der mindestens eines der Dihydroxylcholesterine der Formel (II-b) aus der durch Inkubation behandelten Lösung isoliert wird.
  7. Verfahren nach Anspruch 6, wobei die Inkubationsbehandlung in der Stufe (A) außerdem in Anwesenheit methylierter Cyclodextrine durchgeführt wird.
  8. Dihydroxycholesterin der Formel (II-b):
    Figure 00430001
    worin R2 und R3 eine Hydroxylgruppe bzw. ein Wasserstoffatom bedeuten.)
EP96927894A 1995-08-28 1996-08-26 Dihydroxycholesterine und verfahren zur herstellung von hydrolierten cholesterinen durch biologische umwandlung Expired - Lifetime EP0855445B1 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP24046195 1995-08-28
JP240461/95 1995-08-28
JP24046195 1995-08-28
JP31975895 1995-11-15
JP319758/95 1995-11-15
JP31975895 1995-11-15
JP32125095 1995-11-16
JP321250/95 1995-11-16
JP32125095 1995-11-16
PCT/JP1996/002369 WO1997008336A1 (fr) 1995-08-28 1996-08-26 Procede de production de cholesterols hydroxyles par conversion biologique et dihydroxycholesterols obtenus selon ce procede

Publications (3)

Publication Number Publication Date
EP0855445A1 EP0855445A1 (de) 1998-07-29
EP0855445A4 EP0855445A4 (de) 1998-09-30
EP0855445B1 true EP0855445B1 (de) 2003-03-12

Family

ID=27332829

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96927894A Expired - Lifetime EP0855445B1 (de) 1995-08-28 1996-08-26 Dihydroxycholesterine und verfahren zur herstellung von hydrolierten cholesterinen durch biologische umwandlung

Country Status (8)

Country Link
US (2) US6146844A (de)
EP (1) EP0855445B1 (de)
JP (1) JP3742435B2 (de)
AT (1) ATE234363T1 (de)
AU (1) AU6754696A (de)
DE (1) DE69626656T2 (de)
DK (1) DK0855445T3 (de)
WO (1) WO1997008336A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049829A1 (fr) * 1996-06-27 1997-12-31 Mercian Corporation Procede biologique servant a preparer des steroides 25-hydroxyles
US7556493B2 (en) * 2005-02-24 2009-07-07 Suttle James M Methods and apparatus for molding chocolate
CN111892637B (zh) * 2020-07-16 2022-10-14 山东海能生物工程有限公司 一种7-脱氢-25-羟基胆固醇的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4204995A (en) * 1978-03-15 1980-05-27 Hoffmann-La Roche Inc. Cholestane derivatives
JPH04356190A (ja) * 1990-05-08 1992-12-09 Taisho Pharmaceut Co Ltd ビタミンｄ類の製造方法
JP3201411B2 (ja) * 1990-06-15 2001-08-20 メルシャン株式会社 ビタミンｄ類の生物学的製造方法
WO1994000576A1 (en) * 1992-06-25 1994-01-06 Taisho Pharmaceutical Co., Ltd. Vitamin d hydroxylase gene
JP3589685B2 (ja) * 1993-11-02 2004-11-17 中外製薬株式会社 ステロイド類の２５位水酸化物の生物学的製造法
JPH07241197A (ja) * 1994-01-11 1995-09-19 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンｄ類の製造法

Also Published As

Publication number Publication date
US6410759B1 (en) 2002-06-25
AU6754696A (en) 1997-03-19
US6146844A (en) 2000-11-14
DE69626656D1 (de) 2003-04-17
ATE234363T1 (de) 2003-03-15
EP0855445A4 (de) 1998-09-30
DK0855445T3 (da) 2003-06-30
EP0855445A1 (de) 1998-07-29
DE69626656T2 (de) 2003-09-18
JP3742435B2 (ja) 2006-02-01
WO1997008336A1 (fr) 1997-03-06

Similar Documents

Publication Publication Date Title
KR960004452B1 (ko) 비타민 d 화합물의 제조 방법
WO2004050890A1 (ja) マクロライド系化合物の製造方法
US4512975A (en) Macbecin derivatives and their production
CA1185550A (en) Macbecin derivatives and their production
EP0855445B1 (de) Dihydroxycholesterine und verfahren zur herstellung von hydrolierten cholesterinen durch biologische umwandlung
CA2044550C (en) Method for the biological preparation of hydroxyvitamin d compounds
US6043050A (en) Biological process for producing steroids hydroxylated at the 25-position
KR100536676B1 (ko) 콜히콘 화합물로부터 효소법에 의한 대응하는 3-글리코실유도체로의 변형방법
US4520102A (en) Microbial process for producing 12α-hydroxypregna-1,4-dien-3-one-20α-carboxylic acid
EP0916736B1 (de) Biologisches verfahren zur herstellung von 25-hydroxylierten steroiden
JP3589685B2 (ja) ステロイド類の２５位水酸化物の生物学的製造法
JP4606523B2 (ja) ステロイド類の２５位水酸化物の生物学的製造方法
JP3735393B2 (ja) １α−ヒドロキシビタミンＤ類の製造方法
JPH07241197A (ja) ２５−ヒドロキシビタミンｄ類の製造法
US4923403A (en) Microbiological process for degradation of steroids
JP4439079B2 (ja) プラバスタチンの製造方法
JPH04356190A (ja) ビタミンｄ類の製造方法
JP3957053B2 (ja) 新規な微生物及びプラバスタチンの製造方法
US4214052A (en) Process for preparing 9α-OH BN alcohol
Winter et al. The 21-acetylation of corticosteroids by Clostridium sporogenes
JPH02469A (ja) ビタミンｄ類の製造方法
EP0088007B1 (de) Mikrobiologisches Verfahren zur Herstellung von 12-Hydroxy-androsta-1,4-dien-3,17-dion
EP0061737A1 (de) Verfahren zur Herstellung von Adriamycin
JPH05268944A (ja) 新規胆汁酸変換微生物、及び胆汁酸の製造方法
JPH0120878B2 (de)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980817

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001229

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YOSHIOKA, TAKEO

Inventor name: DOBASHI, KAZUYUKI

Inventor name: TERASAWA, TADASHI

Inventor name: TAKEDA, KOJI

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030312

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69626656

Country of ref document: DE

Date of ref document: 20030417

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030612

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030612

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030826

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030930

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20031215

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040723

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20040813

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040825

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20040902

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050826

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060301

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060428

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060428